There are 9,000 new cases of MCC in these markets.
According to DelveInsight, the Merkel Cell Carcinoma (MCC) market is worth $410 million.
The report estimates that there are about 9,000 new MCC cases in these markets, including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom and Japan.
The treatment of local MCC usually involves surgery and radiation. Advanced cases require systemic therapy, such as immune checkpoint inhibitors, such as AVELUMAB.
Chemotherapy, once the standard treatment for advanced MCC, has limited effects and low effects due to its limited long-term benefits, providing temporary tumor contraction, but with high recurrence rates and significant side effects.
The MCC market is expected to grow due to awareness, early detection and approval of new therapies such as immune checkpoint inhibitors. Government funding and policies are further driving growth. Emerging treatments and improved diagnostic technologies are expected to facilitate market expansion.
Challenges include the rarity of the disease, which limits clinical trials and prevents drug investment.
Addition, high immunotherapy costs can cause access problems, especially in areas with limited healthcare coverage.
Regulatory barriers and delayed diagnosis due to low awareness have also brought significant obstacles to market growth.
